- Home
- AVNS vs ANAB Comparison
AVNS vs ANAB Comparison
Compare AVNS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNS | ANAB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AVNS | ANAB |
|---|---|---|
| Price | $24.95 | $58.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.2M | 497.4K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 81.59 | ★ 91.02 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $701,200,000.00 | $234,603,000.00 |
| Revenue This Year | $3.28 | N/A |
| Revenue Next Year | $4.23 | $52.14 |
| P/E Ratio | $226.55 | ★ N/A |
| Revenue Growth | 1.95 | ★ 157.01 |
| 52 Week Low | $9.30 | $17.11 |
| 52 Week High | $25.49 | $73.30 |
Technical Indicators
Market Signals| Indicator | AVNS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 66.44 | 52.52 |
| Support Level | $24.64 | $52.32 |
| Resistance Level | $24.91 | $67.69 |
| Average True Range (ATR) | 0.08 | 2.86 |
| MACD | -0.12 | 0.93 |
| Stochastic Oscillator | 10.87 | 67.74 |
Price Performance
Historical ComparisonAbout AVNS Avanos Medical Inc.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).